TickerKhojComparison · NSE · data 2026-11-02
Anupam Rasayan India Ltd. vs NATCO Pharma Limited
In plain words
Size: NATCO Pharma Limited is about 1.2 times the market value of Anupam Rasayan India Ltd..
Valuation (P/E): Anupam Rasayan India Ltd. 74.3 vs NATCO Pharma Limited 12.4.
Return on equity: NATCO Pharma Limited 16.9% vs Anupam Rasayan India Ltd. 5.5%.
Profit growth over 3 years: NATCO Pharma Limited 25.6% a year vs Anupam Rasayan India Ltd. -2% a year.
Debt to equity: Anupam Rasayan India Ltd. 0.57 vs NATCO Pharma Limited 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ANURAS | NATCOPHARM | |
|---|---|---|
| Price | ₹1,142.1 | ₹784.7 |
| Market cap | ₹12,999 cr | ₹15,350 cr |
| P/E | 74.3 | 12.4 |
| P/B | — | — |
| ROE | 5.5% | 16.9% |
| ROCE | 9.0% | 15.6% |
| Debt / equity | 0.57 | 0.08 |
| Operating margin | 15.7% | 24.6% |
| Dividend yield | 0.13% | 0.57% |
| Sales growth, 3 years (yearly) | 14.1% | 14.5% |
| Profit growth, 3 years (yearly) | -2.0% | 25.6% |
| 1-year return | 4.0% | -5.1% |
| Revenue, last 12 months | ₹2,535 cr | ₹3,485 cr |
| Net profit, last 12 months | ₹175 cr | ₹1,144 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹39 cr | ₹207 cr |
| Quarter profit vs a year earlier | +13.5% | -57.0% |
| Promoter holding | 59.07% | 49.39% |
| Health check | Weak (3.8/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Anupam Rasayan India Ltd. or NATCO Pharma Limited?
Anupam Rasayan India Ltd. trades at the higher P/E (74.3 against 12.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
NATCO Pharma Limited (16.9% against 5.5%).
Which carries more debt?
Anupam Rasayan India Ltd. has the higher debt-to-equity ratio (0.57 against 0.08).